Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C$_{\text{max}}$ and improved tolerability, in patients with solid tumors

Jaffer A. Ajani$^1$ · Milind Javle$^1$ · Cathy Eng$^1$ · David Fogelman$^1$ · Jackie Smith$^1$ · Barry Anderson$^2$ · Chun Zhang$^3$ · Kenzo Iizuka$^3$

Received: 31 July 2019 / Accepted: 15 April 2020 / Published online: 6 May 2020
© The Author(s) 2020

Summary
5-fluorouracil (5-FU) and 5-FU derivatives, such as capecitabine, UFT, and S-1, are the mainstay of chemotherapy treatment for gastrointestinal cancers, and other solid tumors. Compared with other cytotoxic chemotherapies, these drugs generally have a favorable safety profile, but hematologic and gastrointestinal toxicities remain common. DFP-11207 is a novel oral cytotoxic agent that combines a 5-FU pro-drug with a reversible DPD inhibitor and a potent inhibitor of OPRT, resulting in enhanced pharmacological activity of 5-FU with decreased gastrointestinal and myelosuppressive toxicities. In this Phase I study (NCT02171221), DFP-11207 was administered orally daily, in doses escalating from 40 mg/m$^2$/day to 400 mg/m$^2$/day in patients with esophageal, colorectal, gastric, pancreatic or gallbladder cancer ($n=23$). It was determined that DFP-11207 at the dose of 330 mg/m$^2$/day administered every 12 hours was well-tolerated with mild myelosuppressive and gastrointestinal toxicities. The pharmacokinetic analysis determined that the 5-FU levels were in the therapeutic range at this dose. In addition, fasted or fed states had no influence on the 5-FU levels (patients serving as their own controls). Among 21 efficacy evaluable patients, 7 patients had stable disease (33.3%), of which two had prolonged stable disease of $>6$ months duration. DFP-11207 can be explored as monotherapy or easily substitute 5-FU, capecitabine, or S-1 in combination regimens.

Keywords 5-FU derivative · Chemotherapy · Solid tumor · Dihydropyrimidine dehydrogenase

Introduction
5-Fluorouracil (5-FU), an antimetabolite, was introduced by Heidelberger et al. [1] in 1957, and has since been widely used as a single agent or in combination with other drugs [2–4] mainly in localized or metastatic gastrointestinal cancers and breast cancer. Clinical response and toxicity of 5-FU are remarkably influenced by its dosing schedule and a prolonged exposure by continuous infusion of 5-FU has been found to increase tumor response rates [5–12].

Seeking the efficacy advantage of a continuous infusion 5-FU schedule and in order to enhance patient compliance [13, 14], several oral 5-FU derivatives such as capecitabine [15], tegafur-uracil (UFT) [16] and tegafur-gimeracil-oteracil (S-1) [17] have been developed. Available oral fluoropyrimidines, although considered efficacious have toxicities that remain an ongoing concern. The primary dose-limiting toxicity of capecitabine, UFT, and S-1 has been shown to be hand-foot syndrome [18], gastrointestinal toxicity [19] and hematological toxicity [20], respectively.

A second generation oral fluoropyrimidine, UFT, that combines tegafur [5-fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedione] with the DPD inhibitor uracil, has shown significantly less hematological and gastrointestinal toxicity [21–23]. A fourth generation oral fluoropyrimidine, S-1, that combines tegafur with 5-chloro-2,4-dihydroxypyrimidine (CDHP; a reversible inhibitor of 5-FU degradation [24–27]), and potassium oxonate [potassium 1,3,5-triazine 2,4(1H,3H)-dione-6-carboxylate] that inhibits orotate phosphoribosyltransferase, the enzyme that phosphorylates 5-FU in the
gastrointestinal tract, demonstrated further reduction in gastrointestinal toxicity of 5-FU [17, 24, 27–33].

Tumor-selective cytotoxicity of S-1 was confirmed in two Phase I [24, 33] and four Phase II trials in patients with advanced gastric or colorectal cancer [20, 34–36], which led to approval of S-1 for patients with advanced gastric cancer in Japan [34]. In all of the above studies hematological toxicity was predominant, with only a few or no cases of ≥ Grade 3 gastrointestinal toxicity. Notably, hematological toxicities predominated in the studies conducted in Japan, and gastrointestinal toxicity was the DLT in Europe and the United States [20, 24, 25, 33–37], likely due to a lower expression of the cytochrome P4502A6 (CYP2A6) isozyme in Japanese individuals [24, 25, 34, 35, 38–42].

Interindividual and intraindividual variations in plasma 5-FU concentrations are mainly caused by differing levels of dihydropyrimidine dehydrogenase (DPD), the primary catabolic enzyme of 5-FU [43–45]. Deficiency of DPD is associated with severe hematologic and gastrointestinal toxicity after 5-FU administration [46]. Inhibition or inactivation of DPD has emerged as a potential strategy to reduce the pharmacokinetic variability and improve the efficacy of 5-FU [12, 47].

To minimize the 5-FU-induced toxicities without compromising its antitumor activity, Delta-Fly Pharma, Inc. has developed DFP-11207, a novel cytotoxic agent that combines a 5-FU pro-drug (1-ethoxymethyl-5-fluorouracil; EMFU) [26] with a reversible DPD inhibitor CDHP [48] and a potent inhibitor of orotate phosphoribosyl transferase (citrazinic acid; CTA). This combination results in enhanced pharmacological activity of 5-FU, with lower Cmax and AUC values but longer Tmax and T1/2 values of 5-FU, respectively than S-1, which suggests that DFP-11207 may be superior in preventing the 5-FU-induced severe hematological and gastrointestinal toxicities. CTA, that is mainly retained in gastrointestinal tract cells, protects the gastrointestinal tract from injury by inhibiting 5-FU phosphorylation.

DFP-11207’s self-controlled toxicity profile may allow this molecule to improve the tolerability and efficacy of 5-FU-based treatment for cancer patients as a monotherapy or in combination therapy [49].

The primary objective of this study was to determine the maximum tolerated dose (MTD), the recommended Phase II dose (RP2D) and the dose-limiting toxicity (DLT) of DFP-11207 in patients with advanced solid tumors, and to assess pharmacokinetic (PK) profiles of DFP-11207 under fed and fasted conditions. Secondary objectives were to perform PK analysis of DFP-11207 and to assess the antitumor activity of DFP-11207 in patients with advanced solid tumors.

**Eligibility**

Eligible patients were males or females of at least 18 years of age, with solid tumors refractory by standard therapies or for which conventional chemotherapy was not reliably effective or no effective therapy was available. Patients must have had adequate bone marrow function as defined by absolute neutrophil count of ≥1.5 × 10⁹/L and platelets of ≥100 × 10⁹/L. Adequate liver and kidney function were required. Patient who had current malignancies of another type, patients after extensive prior radiotherapy, or prior bone marrow/stem cell transplantation, and patients with clinically evident CNS metastases or leptomeningeal disease were not eligible for the study. Prior exposure to chemotherapy, immunotherapy, radiotherapy or any other investigational therapy within 4 weeks was not permitted. Patients with cardiac dysfunction and known bleeding disorder were excluded.

**Treatment**

In the Phase I Study, patients received DFP-11207 capsules orally, daily in 28-day cycles. Patients in the 40 to 250 mg/m²/day cohorts received once-daily DFP-11207 dosing. For patient compliance, the DFP-11207 dosing schedule was changed at doses of 330 mg/m²/day (1 patient) or 440 mg/m²/ day (4 patients) to every 12 hours on all treatment days except on Cycle 1, Days 1 and 29, when DFP-11207 was administered as a single dose for PK sampling purposes and later for the subsequent 5 patients in the 330 mg/m²/day cohort, DFP-11207 dosing schedule was changed to every 12 hours on all treatment days. Subsequently, a Food Effect Study was added, and 6 patients were treated with DFP-11207 at the dose of 600 mg/day administered as 300 mg every 12 hours.

**Criteria for evaluation**

**Safety** Safety data including laboratory parameters, vital signs, and adverse events were collected for all patients. All patients who received any amount of DFP-11207 were included in the safety analysis. Safety parameters evaluated include adverse events, vital signs, and clinical laboratory results. Adverse events were classified according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.
Efficacy Although response was not the primary endpoint of this study, patients with measurable disease were assessed using RECIST version 1.1, where possible after every 2 cycles. For patients with less than 2 cycles of study therapy, if there was clear evidence of clinical progression then they were considered eligible for the efficacy evaluation.

Plasma pharmacokinetics, phase I study Following oral administration of DFP-11207, blood samples were collected during Cycle 1 on Day 1 at 0 hour (pre-dose), 1, 2, 4, 8, 12, 24, and 48 hours after the study drug administration and thereafter, on day 15 pre-dose (added per amendment 2 to monitor every 12 hours dosing) and day 29, pre-dose and 4 hours after DFP-11207 administration. DFP-11207 metabolites: 5-fluorouracil (5-FU), 1-ethoxymethyl-5-fluorouracil (EM-FU), 5-chloro-2,4-dihydroxypyridine (CDHP), and citrazinic acid (CTA) were then measured.

Plasma pharmacokinetics, food effect study Following oral administration of DFP-11207, blood samples were collected during Cycle 1 (fed or fasted study days) on Day 1 at 0 hour (pre-dose), and 4, 10, 24 and 48 hours after the study drug administration, Day 8 at 2 hours after the morning DFP-11207 administration, Day 14 at 2, 10 and 24 hours after DFP-11207 administration, Day 16 at 0 hour (pre-dose), and 4, 10 and 24 hours after DFP-11207 administration, Day 18 at pre-dose, Day 23 at 2 hours after the morning DFP-11207 administration, Day 29 at 2, 10 and 24 hours after DFP-11207 administration, and pre-dose on Cycle 2 Day 1.

For both the Phase I Study and the Food Effect Study, whole blood (5 mL) was collected in chilled heparin collection tubes to harvest plasma. High performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) was used to determine plasma and urine concentrations of DFP-11207 metabolites 5-FU, EM-FU, CDHP, and CTA.

Urine pharmacokinetics, phase I study Urine samples (8 mL) were also collected and pooled at pre-dose (~12 to 0 hour) and after the start of DFP-11207 treatment at: 0 to 12 hours, 12 to 24 hours, 24 to 36 hours, and 36 to 48 hours. DFP-11207 metabolites were then measured.

Statistical approach

The primary endpoint of this study was to assess the toxicity of DFP-11207 by determining the dose level at which DLTs were observed. AEs were arranged by decreasing frequency of AEs. Laboratory data was graded according to NCI CTCAE (Version 4.0) and tabulated based on maximum grade. AEs were coded using the Medical Dictionary for Drug Regulatory Activities (MedDRA®) Version 17.0.

Secondary endpoints of this study were to examine the efficacy and PKs of DFP-11207. For efficacy analysis, overall response was assessed using RECIST version 1.1. The objective antitumor response rate [complete response (CR) or partial response (PR)] was calculated as the proportion of patients with responsive disease (CR + PR) and 95% confidence interval for response was calculated for the median time. Duration of response and time to tumor progression were evaluated using Life Table methods. Life Table estimates were calculated using Kaplan-Meier methodology.

Plasma concentration and time data of DFP-11207 metabolites (5-FU, EM-FU, CDHP and CTA) in the Food Effect Study were determined using non-compartmental methods (WinNonLin®). PK parameters to be calculated included AUC extrapolated to infinity (AUC inf), peak concentration (Cmax), time at Cmax (Tmax) and elimination half-life (T1/2). Statistical analysis of PK parameters was to be performed to compare each fed condition to the fasted condition by using analysis of variance which were compared by using the Wilcoxon matched-pairs test.

Results

Patient demographics

Among 23 patients enrolled in the study, 13 patients (56.5%) were men and 10 patients (43.5%) were women. The median patient age was 59 years (overall age range: 36 to 86 years) and median body surface area (BSA) was 1.94 m² (range: 1.57 to 2.58). Seventeen patients (73.9%) were White, 3 patients (13.0%) were Black or African American, 2 patients (8.7%) were Asian and 1 patient (4.3%) was of other race. At baseline, 5 patients (21.7%) had Eastern Cooperative Oncology Group (ECOG) performance status of 0 and 18 patients (78.3%) had ECOG performance status of 1.

Baseline disease characteristics

The majority of patients (19 patients; 82.6%) had histopathology diagnosis of adenocarcinoma not otherwise specified (NOS); 4 patients (17.4%) had carcinoma NOS as the predominant histopathology with primary tumors sites of esophagus or rectum (both 6 patients each), large intestine (4 patients), pancreas or stomach (3 patients each) and gallbladder and extrahepatic bile duct (1 patient) (see Tables 1, 2 and 3).

All 23 patients had prior surgery and chemotherapy; 13 patients (56.5%) had prior radiation therapy; 2 patients (8.7%) had prior immunotherapy. In addition, 13 patients (56.5%) had other prior therapy (see Table 1).

Treatment

During the Phase I Study, DFP-11207 dose escalation progressed in accelerated single patient cohorts from 40 mg/
### Table 1  Prior cancer therapy

| Prior therapy | 40 | 80 | 110 | 140 | 190 | 250 | 330 | 440 | 600 mg/day | Overall |
|---------------|----|----|-----|-----|-----|-----|-----|-----|-------------|---------|
| Number of patients | 1 | 2 | 1 | 1 | 1 | 1 | 6 | 4 | 6 | 23 |
| Number of patients with: | | | | | | | | | | |
| Prior chemotherapy | 1 (100.0%) | 2 (100.0%) | 1 (100.0%) | 1 (100.0%) | 1 (100.0%) | 6 (100.0%) | 4 (100.0%) | 6 (100.0%) | 23 (100.0%) |
| Prior immunotherapy | 0 | 1 (50.0%) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (16.7%) | 2 (8.7%) |
| Other prior therapy | 1 (100.0%) | 2 (100.0%) | 1 (100.0%) | 1 (100.0%) | 0 | 1 (100.0%) | 4 (66.7%) | 2 (50.0%) | 1 (16.7%) | 13 (56.5%) |
| Prior radiation therapy | 0 | 2 (100.0%) | 1 (100.0%) | 0 | 1 (100.0%) | 1 (100.0%) | 4 (100.0%) | 2 (33.3%) | 3 (75.0%) | 3 (50.0%) | 13 (56.5%) |
| Prior surgery | 1 (100.0%) | 2 (100.0%) | 1 (100.0%) | 1 (100.0%) | 1 (100.0%) | 6 (100.0%) | 4 (100.0%) | 6 (100.0%) | 23 (100.0%) |

1 Patients may be counted in more than one prior therapy category
2 Number of patients used as denominator to calculate percentages

### Table 2  Baseline disease characteristics

| Disease characteristics | 40 | 80 | 110 | 140 | 190 | 250 | 330 | 440 | 600 mg/day | Overall |
|-------------------------|----|----|-----|-----|-----|-----|-----|-----|-------------|---------|
| Number of Patients | 1 | 2 | 1 | 1 | 1 | 1 | 6 | 4 | 6 | 23 |
| Histopathology | | | | | | | | | | |
| Adenocarcinoma, NOS | 0 | 2 (100.0%) | 0 | 1 (100.0%) | 0 | 1 (100.0%) | 6 (100.0%) | 3 (75.0%) | 6 (100.0%) | 19 (82.6%) |
| Carcinoma, NOS | 1 (100.0%) | 0 | 1 (100.0%) | 0 | 1 (100.0%) | 0 | 0 | 1 (25.0%) | 0 | 4 (17.4%) |
| Primary site | | | | | | | | | | |
| Esophagus | 0 | 1 (50.0%) | 0 | 0 | 0 | 0 | 0 | 1 (16.7%) | 2 (50.0%) | 6 (26.1%) |
| Rectum | 0 | 0 | 0 | 0 | 1 (100.0%) | 0 | 1 (16.7%) | 1 (25.0%) | 3 (50.0%) | 6 (26.1%) |
| Large intestine, (excl. appendix) | 1 (100.0%) | 0 | 0 | 0 | 1 (100.0%) | 0 | 2 (33.3%) | 0 | 3 (13.0%) |
| Pancreas | 0 | 1 (50.0%) | 0 | 1 (100.0%) | 0 | 0 | 1 (16.7%) | 0 | 0 | 4 (17.4%) |
| Stomach | 0 | 0 | 0 | 0 | 0 | 0 | 1 (16.7%) | 1 (25.0%) | 1 (16.7%) | 3 (13.0%) |
| Gallbladder & extrahepatic bile ducts | 0 | 0 | 1 (100.0%) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (4.3%) |

1 Number of treated patients used as denominator to calculate percentages
m²/day up to 330 mg/m²/day; no Grade 2 or greater DFP-11207-related AEs were observed during Cycle 1 of dosing at these doses (Fig. 1). At 440 mg/m²/day, the first patient enrolled in the dose cohort experienced DFP-11207-related AEs of Grade 3 dehydration and mucosal inflammation and Grade 4 febrile neutropenia. Per protocol, the 440 mg/m²/day cohort was expanded to 3 patients. The 3rd patient enrolled in the 440 mg/m²/day cohort experienced a Grade 4 febrile neutropenia. As per the Safety Review Committee assessment, Grade 4 febrile neutropenia was considered a DLT. Thus, dose escalation was stopped, and 440 mg/m²/day was declared to be the maximum administered dose (MAD).

Five additional patients were treated every 12 hours at 330 mg/m²/day, the dose below 440 mg/m²/day. In total, during the Phase I Study, 6 patients - 1 during the dose escalation phase and 5 during the MTD confirmation phase - were treated at 330 mg/m²/day. No DLTs were reported at the dose of 330 mg/m²/day. Therefore, 330 mg/m²/day administered every 12 hours was confirmed as the MTD, which is also the RP2D. In the Food Effect Study, all 6 patients were treated with DFP-11207 at the dose of 600 mg/day administered as 300 mg every 12 hours; no DLTs were reported.

### Adverse events

A summary of the ≥ Grade 3 treatment emergent adverse events (TEAEs) that were reported during the study is presented in Table 4. All 23 safety evaluable patients who received DFP-11207 treatment (17 patients in the Phase I Study, 6 patients in the Food Effect Study) experienced at least 1 TEAE. A total of 16 patients (69.6%) reported TEAEs related to DFP-11207. The incidence of ≥ Grade 3 drug-related TEAEs was 13.0% (3/23 patients; all in the Phase I Study including, 1/6 patients in the 330 mg/m²/day cohort and 2/4 patients in the 440 mg/m²/day cohort). The most frequently reported (≥ 10% of patients) ≥ Grade 3 events were dysphagia (13.0%), dehydration (13.0%), and failure to thrive (13.0%). The most common ≥ Grade 3 drug-related hematologic AE reported in 440 mg/m²/day cohort was febrile neutropenia (2 patients; 8.7%); anemia (1 patient; 4.3%) and pancytopenia (1 patient; 4.3%). Notably, no patient experienced any ≥ Grade 3 drug-related thrombocytopenia. Two patients (8.7%) in the Phase I Study had drug-related SAEs. There was no death related to DFP-11207 treatment. DFP-11207 dose interruption due to TEAEs occurred in 34.8% of patients (8/23 patients; all in the Phase I Study including, 1/2 patients in the 80 mg/m²/day cohort; 1/1 patient in the 250 mg/m²/day cohort, 2/6 patients in the 330 mg/m²/day cohort, and 4/4 patients in the 440 mg/m²/day cohort), indicating DFP-11207 was well-tolerated at the RP2D level of 330 mg/m²/day every 12 hours.

Overall, the most frequently reported drug-related TEAEs (≥ 10% of patients) were fatigue (47.8%), nausea (47.8%), decreased appetite (39.1%), decreased appetite (39.1%), diarrhea (26.1%), vomiting (21.7%), anemia (13.0%), dysgeusia (13.0%), mucosal inflammation (13.0%) and palmar-plantar erythrodysesthesia syndrome (13.0%). In the Phase I Study, at the MTD/RP2D (330 mg/m²/day), drug-related TEAEs reported were decreased appetite (4 of 6 patients [4/6]), fatigue (4/6), nausea (4/6), vomiting (2/6), diarrhea (1/6), hematemesis (1/6), lacrimation increase (1/6), microcytic anemia (1/6), nail discoloration (1/6), ocular hyperemia (1/6), palmar-plantar erythrodysesthesia syndrome (1/6), pyrexia (1/6), and stomatitis (1/6), of which vomiting was the only ≥ Grade 3 drug-related TEAE (1 patient). In the Food Effect Study, the DFP-11207-related TEAEs reported were fatigue (3 patients; 50%), diarrhea (2 patients; 33.3%), and constipation, decreased

---

**Table 3** Duration of disease at baseline

| Duration of disease (months) | 40 | 80 | 110 | 140 | 190 | 250 | 330 | 440 | 600 mg/day | Overall |
|------------------------------|----|----|-----|-----|-----|-----|-----|-----|-------------|---------|
| N                            | 1  | 2  | 1   | 1   | 1   | 1   | 6   | 4   | 6           | 23      |
| Mean                         | 13.24 | 23.44 | 29.34 | 20.99 | 19.88 | 62.82 | 51.53 | 15.60 | 38.43       | 34.58   |
| Standard deviation           | 0.813 | 40.595 | 7.891 | 33.519 | 29.564 | 40.595 | 7.891 | 33.519 | 29.564      |         |
| Median                       | 13.24 | 23.44 | 29.34 | 20.99 | 19.88 | 62.82 | 41.89 | 16.92 | 30.85       | 23.59   |
| Minimum                      | 13.2 | 22.9 | 29.3 | 21.0 | 19.9 | 62.8 | 10.0 | 5.0 | 9.9         | 5.0     |
| Maximum                      | 13.2 | 24.0 | 29.3 | 21.0 | 19.9 | 62.8 | 115.3 | 23.6 | 103.1       | 115.3   |

---

**Fig. 1** Disposition of patients (N = 23)
appetite, insomnia, mucosal inflammation, paresthesia, urinary tract infection, vomiting (1 patient each; 16.7%). No ≥ Grade 3 TEAEs were reported in the Food Effect Study.

Pharmacokinetics

The PK data at 330 and 440 mg/m²/day indicate that dose-dependent plasma 5-FU concentrations ranged from 4.01 to 25.5 ng/mL and 3.39 to 13.0 ng/mL on Cycle 1, Day 2 and 5.27 to 23.5 ng/mL and 23 to 45.3 ng/mL on Cycle 1, Day 29 (pre-dose), respectively. Plasma EM-FU concentrations at 330 and 440 mg/m²/day ranged from 559 to 1380 ng/mL and 948 to 1770 ng/mL on Cycle 1, Day 2 and 2510 to 5120 ng/mL and 3440 to 5900 ng/mL on Cycle 1, Day 29 (pre-dose), respectively. Plasma 5-FU and EM-FU concentrations on Cycle 1, Day 15 (pre-dose) at the dose of 330 mg/m²/day ranged from 9.21 to 119 ng/mL and 2760 to 8750 ng/mL, respectively (Table 5). Day 29 plasma concentrations for all analytes were higher than Day 1 plasma concentrations at the same timepoint, suggesting accumulation with repeat daily dosing of DFP-11207. Overall, the PK data suggest that DFP-11207 at these dose levels maintain blood concentrations of 5-FU of approximately 20 ng/mL throughout the dose cycle in patients with advanced solid tumors. In contrast, the urinary excretion of 5-FU, EM-FU, CDHP and CTA during Cycle 1 0–48 hours after the DFP-11207 dose of 330 mg/m²/day accounted for 0.12, 0.71, 1.98 and 0.07%, respectively.

Among 6 patients receiving a DFP-11207 dose of 300 mg twice daily both with food or without food the PK results determined that EM-FU and CDHP were detectable in plasma at all time points of assessment during fed and fasted dosing. While 5-FU and CTA plasma levels had more variability in patients, there were no clear differences in C_{max} or AUC_{last} between DFP-11207 taken under fasted and fed conditions (Table 6). An approximately 1.5- to 3-fold increase in AUC_{last} was observed following the steady state dose compared to the initial dose. Based on these results, DFP-11207 bioavailability does not appear to differ substantially whether patients are administered DFP-11207 in a fed or fasted state (Fig. 2).

### Table 4
Summary of ≥ grade 3 treatment-emergent adverse events by system organ class and preferred term

| MedDRA System Organ Class | MedDRA Preferred Term | DFP-11207 Dose cohort (mg/m²/day) |
|---------------------------|-----------------------|----------------------------------|
|                           |                       | 330     | 440     | 600 mg/day |
| Number of patients        | 6                     | 4       | 6       |
| Number of Patients with Any Grade 3 or Greater, Drug-Related, TEAEs | 1 (16.7%) | 2 (50.0%) | 0 |
| Blood and lymphatic system disorders | 0 | 2 (50.0%) | 0 |
| Febrile neutropenia       | 0                     | 2 (50.0%) | 0 |
| Anemia                    | 0                     | 1 (25.0%) | 0 |
| Pancytopenia              | 0                     | 1 (25.0%) | 0 |
| Gastrointestinal disorders | 1 (16.7%) | 0 | 0 |
| Vomiting                  | 1 (16.7%) | 0 | 0 |
| General disorders and administration site conditions | 0 | 1 (25.0%) | 0 |
| Mucosal inflammation      | 0                     | 1 (25.0%) | 0 |
| Metabolism and nutrition disorders | 0 | 1 (25.0%) | 0 |
| Dehydration               | 0                     | 0       | 0       |

### Table 5
Summary of Plasma PK Parameters by Analyte Following Dosing of 330 and 440 mg/m² Oral DFP-11207 on Day 1 in Patients with Solid Tumors

| Dose level (mg/m²) | Parameter (unit) | Statistic | EM-FU | 5-FU | CDHP | CTA |
|--------------------|------------------|-----------|-------|------|------|-----|
|                    | T\textsubscript{max} (h) | N: Median (Min, Max) | 6; 48 (24, 48) | 6; 24 (24, 48) | 6; 24 (8.0, 48) | 5; 8.0 (2.0, 48) |
|                    | C\textsubscript{max} (ng/mL) | N: Mean (SD) | 6; 1310 (370) | 6; 9.65 (8.25) | 6; 90.4 (39.7) | 5; 9.81 (5.68) |
|                    | AUC\textsubscript{last} (ng·h/mL) | N: Mean (SD) | 6; 39,900 (8950) | 1; 220 | 6; 2410 (1080) | 4; 254 (134) |
| 440                | T\textsubscript{max} (h) | N: Median (Min, Max) | 4; 24 (24, 48) | 3; 12 (8.0, 48) | 4; 26 (2.0, 48) | 3; 4.0 (4.0, 8.0) |
|                    | C\textsubscript{max} (ng/mL) | N: Mean (SD) | 4; 1400 (595) | 3; 8.75 (5.24) | 4; 93.6 (60.5) | 3; 9.72 (6.53) |
|                    | AUC\textsubscript{last} (ng·h/mL) | N: Mean (SD) | 4; 49,400 (18200) | 3; 311 (214) | 4; 2810 (2150) | 2; 388 (237) |
Efficacy

Among 21 efficacy evaluable patients, 7 patients had stable disease (33.3%; 2 patients in the 330 mg/m²/day cohort and 1 patient each in the 250 and 440 mg/m²/day cohorts of the Phase I Study, and 3 patients in the Food Effect Study treated at the dose of 600 mg/day); no patients achieved CR or PR (Table 7). Among the 7 patients with stable disease, 2 patients
in the Phase I Study had prolonged stable disease of over 6 months duration, 238 days (67-year-old male with colon cancer in the 330 mg/m²/day cohort) and 341 days (37-year-old female with colon cancer in the 250 mg/m²/day cohort) respectively, suggesting clinical benefit for DFP-11207.

Discussion

The patient experience in this Phase I dose escalation study of DFP-11207 indicates successful implementation of a two-pronged strategy to control the toxicity of orally administered 5-FU while maintaining effective circulating levels of 5-FU. CTA is mainly retained in the gastrointestinal tract cells where it inhibits 5-FU phosphorylation, thus protecting the gastrointestinal tract from injury as the 5-FU is absorbed into the circulation. Secondly, CDHP reversibly inhibits DPD to delay the enzymatic degradation of 5-FU in the circulation while associated with the degradation of 5-FU prodrug, resulting in a prolonged systemic 5-FU exposure profile with lower C_{max} and similar AUC compared to S-1. Owing to the concomitant presence of these DFP-11207 components, treatment at the DFP-11207 dose of 330 mg/m²/day administered orally every 12 hours produced a steady state circulating 5-FU level of 5.27–23.5 ng/mL (C_{max} < 25 ng/mL) and was well tolerated without any significant myelosuppression or gastrointestinal toxicity in advanced solid tumor patients, while patients treated at 440 mg/m²/day had steady state circulating 5-FU levels of 23–45.3 ng/mL (C_{max} 49.7–54.7 ng/mL) associated with severe myelosuppression and moderate mucosal inflammation, fatigue and palmar-plantar erythrodysesthesia.

The food-effect study demonstrates maintenance of bioavailability when DFP-11207 is administered as a twice-daily 300 mg flat-dose with or without food (mean steady state levels of 27.6 and 16.7 ng/mL, mean AUC of 809 and 535 ng·h/mL, respectively) and no significant myelosuppressive or gastrointestinal adverse events. These results are in contrast to S-1 for which the maximum tolerated dose of 40 mg/m²/day has an associated 5-FU C_{max} of 128 ng/mL and 5-FU AUC of 724 ng·h/mL [24] and S-1 dosing at 30 mg/m² BID has an associated 5-FU C_{max} of approximately 150 ng/mL and 5-FU AUC of approximately 800 ng·h/mL [50, 51]. S-1 doses above these MTDs were associated with Grade 3 or 4 gastrointestinal and myelosuppressive toxicities.

The PK characteristics of DFP-11207 continuous dosing indicate that 5-FU concentration levels and 5-FU AUCs conducive to an anti-tumor effect and minimal toxicity, supported by preliminary evidence of anti-tumor activity suggest promise for future clinical trials of DFP-11207 in monotherapy or combination with standard chemotherapeutic drugs, specifically as a substitution for 5-FU, capecitabine or S-1 within standard 5-FU or oral 5-FU derivative treatment regimens for the treatment of a variety of 5-FU-responsive cancer indications.
**Funding information** The work was supported by Delta-Fly Pharma, Inc. and by Prof. Jaffer Ajani.

**Compliance with ethical standards**

**Conflicts of interest** Jaffer Ajani declares receiving grants/research support from Delta-Fly Pharma, Inc., ProLyx, Bristol-Myers Squibb, Merck, Astellas, Roche, Zymeworks, Eli Lilly, Taiho Pharmaceutical, and honoraria or consultation fees from Bristol-Myers Squibb, Merck, Astellas, Eli Lilly, AstraZeneca, Daiichi Sankyo, Roche. Milind Javel declare receiving honoraria or consultation fees from Rafael Pharmaceuticals, Incyte, Pieris Pharmaceuticals, Merck, Novartis, Seattle Genetics, Beigene, QED Therapeutics, Bayer. Cathy Eng declares she has no conflict of interest. David Fogelman declares receiving grants / research support from Delta-Fly Pharma, Inc. Jackie Smith declares that she has no conflict of interest. Barry Anderson declares that he has no conflict of interest. Chun Zhang is an employee of Delta-Fly Pharma, Inc. Kenzo Iizuka is an executive officer of Delta-Fly Pharma, Inc.

**Ethical approval** This study was conducted in accordance with International Conference on Harmonization Good Clinical Practice (ICH/GCP), the protocol, all applicable regulatory requirements, and guiding principles of the Declaration of Helsinki and its later amendments.

**Informed consent** Informed consent was obtained from all individual participants included in the study.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Heidelberger C, Chaudhuri NK, Danneberg P et al (1957) Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature. 179(4561):663–666. https://doi.org/10.1038/179663a0
2. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil alone or without oxaliplatin as first-line treatment in advanced colorectal Cancer. J Clin Oncol 18(16):2938–2947. https://doi.org/10.1200/JCO.2000.18.16.2938
3. André T, Louvet C, Maindrault-Goebel F, Couteau C, Mahbub M, Lotz JP, Gilles-Amar V, Kralik M, Carola E, Izrael V, de Gramont A (1999) CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIIRI) for pretreated metastatic colorectal cancer. GERCOR Eur J Cancer 35(9):1343–1347. http://www.ncbi.nlm.nih.gov/pubmed/10658525.

4. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer. 71(12):3813–3818. http://www.ncbi.nlm.nih.gov/pubmed/8508349.

5. Caballero GA, Ausman RK, Quebbeman EJ. Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas. Cancer Treat Rep 1985;69(1):13–15. http://www.ncbi.nlm.nih.gov/pubmed/3155649. Accessed March 17, 2019

6. Moynihan T, Hansen R, Anderson T, Quebbeman E, Beatty P, Ausman R, Ritch P, Chittambar C, Vukech I (1988) Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 11(4):461–464. http://www.ncbi.nlm.nih.gov/pubmed/3407626.

7. Barbounis VP, Kalofonos HP, Munro AJ, McKenzie CG, Sackier JM, Epenetos AA. Treatment of colorectal cancer and other malignancies with continuous infusion of 5-fluorouracil. Anticancer Res. 9(1):33–39. http://www.ncbi.nlm.nih.gov/pubmed/2705753. Accessed March 17, 2019

8. Quebbeman E, Ausman R, Hansen R, Becker T, Caballero G, Ritch P, Jenkins D, Blake D, Tangen L, Schulte W (1985) Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil. J Surg Oncol 30(1):60–65. http://www.ncbi.nlm.nih.gov/pubmed/3935873.

9. Lokich JJ, Ahlgren JD, Gullo JJ, Phillips JA, Fryer JG (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J Clin Oncol 7(4):425–432. https://doi.org/10.1200/JCO.1989.7.4.425

10. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A (1995) Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a southwest oncology group study. J Clin Oncol 13(6):1303–1311. https://doi.org/10.1200/JCO.1995.13.6.1303

11. Meta-analysis Group In Cancer, Piedbois P, Rougier P, et al. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol. 1998;16(1):301–308. https://doi.org/10.1200/JCO.1998.16.1.301

12. Iyer L, Ratain MJ (1999) 5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Investig 17(7):494–506. http://www.ncbi.nlm.nih.gov/pubmed/10518194.

13. Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1):110–115. https://doi.org/10.1200/JCO.1997.15.1.110

14. DeMario MD, Ratain MJ (1998) Oral chemotherapy: rationale and future directions. J Clin Oncol 16(7):2557–2567. https://doi.org/10.1200/JCO.1998.16.7.2557

15. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H (1998) Tumor selective delivery of 5-fluorouracil by 1-(2-tetrahydrofuryl)-5-fluorouracil (S-1) against human cancer xenografts. Biochem Pharmacol 55(7):1091–1097. https://doi.org/10.1016/S0006-2952(97)00303-5

16. Fujii S, Ikenaka K, Fukushima M, Shirasaka T (1978) Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gan. 69(6):772–777. https://doi.org/10.1200/JCO.1978.6.6.772

17. Shirasaka T, Nakano K, Takechi T, Satake H, Fujioka A, Fujisaka A, Iizuka K, Takeda S, Umemi N, Fukushima M (1996) Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer
Res 56(11):2602–2606 http://www.ncbi.nlm.nih.gov/pubmed/8653704.
18. Yen-Revollo JL, Goldberg RM, McLeod HL (2008) Clinical cancer research. Clin Cancer Res 12(18):5491–5495. https://doi.org/10.1186/1054-3870-26-O1747
19. Taguchi T (1997) Experience with UFT in Japan. Oncology (Williston Park) 11(9 Suppl 10):30–34 http://www.ncbi.nlm.nih.gov/pubmed/9348564.
20. Sugimaki K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mituchi Y, Taguchi T (1999) An early phase II study of Oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology. 57(3):202–210. https://doi.org/10.1159/000120322
21. Hoff PM, Pazzur R, Benner SE, Canetta R (1998) UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anti-Cancer Drugs 9(6):479–490 http://www.ncbi.nlm.nih.gov/pubmed/9877235.
22. Doullard J-Y, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, Vincent MD, Lembersky BC, Thompson S, Maniero A, Benner SE (2002) Multicenter phase III study of uracil/Tegafur and Oral Leucovorin versus fluorouracil and Leucovorin in patients with previously untreated metastatic colorectal Cancer. J Clin Oncol 20(17):3605–3616. https://doi.org/10.1200/JCO.2002.04.123
23. Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, Skovsgaard T, Munier S, Martin C (2002) Randomized comparative study of Tegafur/uracil and Oral Leucovorin versus parenteral fluorouracil and Leucovorin in patients with previously untreated metastatic colorectal Cancer. J Clin Oncol 20(17):3617–3627. https://doi.org/10.1200/JCO.2002.10.129
24. Hirata K, Horikoshi N, Aiba K et al (1999) Clinical cancer research. Clin Cancer Res 4(9):2085–2088 http://clincancerres.aacrjournals.org/content/5/8/2000.
25. van Groeningen CJ, Peters GJ, Schormagel JH, Gall H, Noordhuis P, de Vries MJ, Turner SL, Swart MS, Pinedo HM, Hanauke AR, Giaccone G (2000) Phase I clinical and pharmacokinetic study of Oral S-1 in patients with advanced solid tumors. J Clin Oncol 18(14):2772–2779. https://doi.org/10.1200/JCO.2000.18.14.2772.
26. Tatsumi K, Fukushima M, Shirasaka T, Fujii S (1997) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78(7):748–755 http://www.ncbi.nlm.nih.gov/pubmed/3114201.
27. Shirasaka T, Shimamoto Y, Oshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two bio-chemical modifiers. Anti-Cancer Drugs 7(5):548–557 http://www.ncbi.nlm.nih.gov/pubmed/8862723.
28. Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53(17):4004–4009 http://www.ncbi.nlm.nih.gov/pubmed/7698420.
29. Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, Unemi N, Shirasaka T (1997) Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39(3):205–211 http://www.ncbi.nlm.nih.gov/pubmed/8996521.
30. Kondo H, Tanaka T, Baba M, Kanai T, Matsumoto K, Kaniyi K, Nakamura S (1999) Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxy pyridine-1 M potassium oxinate (S-1) on liver metastasis of xenotransplanted human colon carcinoma. Jpn J Cancer Res 90(4):448–453 http://www.ncbi.nlm.nih.gov/pubmed/10363584.
31. Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T, Okabe H, Fujioka A, Nakano K, Ohshimo H, Takeda S, Shirasaka T (1998) Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 13(4):693–698 http://www.ncbi.nlm.nih.gov/pubmed/9735397.
32. Fukushima M, Shimamoto Y, Kato T, Uchida J, Yonekura R, Ohshimo H, Shirasaka T (1998) Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anti-Cancer Drugs 9(9):817–823 http://www.ncbi.nlm.nih.gov/pubmed/9840729.
33. Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, Furue H, Kuriraha M, Ota K, Suga S, Ariyoshi Y, Takai S, Shimoyama T, Toge T, Takashima S, Sugimachi K, Hara Y, Fujita H, Kimura K, Saito T, Tsukagoshi S, Nakao I (1997) Phase I study of S-1, S-1 study group. Gan To Kagaku Ryoho. 24(15):2253–2264 http://www.ncbi.nlm.nih.gov/pubmed/9422070.
34. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine antitumor drug S-1 (1 M tegafur-0.4 M m gemistat-1 M m ostat potassium) in advanced gastric cancer patients. Eur J Cancer 34(11):1715–1720 http://www.ncbi.nlm.nih.gov/pubmed/9893658.
35. Koizumi W, Kuriraha M, Nakano S, Hasegawa K (2000) Phase II study of S-1, a novel Oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology. 58(3):191–197. https://doi.org/10.1159/000012099
36. Ohtsu A, Baba H, Sakata Y, Mituchi Y, Horikoshi N, Sugimachi K, Taguchi T (2000) Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 cooperative colorectal carcinoma study group. Br J Cancer 83(2):141–145. https://doi.org/10.1054/bjc.2000.1236.
37. Inuyama Y, Kida A, Tsukada M, Kohno N, Satake B (1998) Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 cooperative study group (head and neck working group). Gan To Kagaku Ryoho 25(8):1151–1158 http://www.ncbi.nlm.nih.gov/pubmed/9679577.
38. Shimada T, Yamazaki H, Guengerich FP (1996) Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P450A2E1 in liver microsomes of Japanese and Caucasian populations. Xenobiotaica 26(4):395–403 http://www.ncbi.nlm.nih.gov/pubmed/9173680.
39. van der Weide J, Steijns LSW (1999) Cytochrome P450 450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem An Int J Biochem Lab Med 36(6):722–729. https://doi.org/10.1177/00045632990360060064.
40. Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon J-T, Yokoi T (2003) Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6·9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 74(1):69–76. https://doi.org/10.1016/S0009-9236(03)00090-0.
41. Daigo S, Takahashi Y, Fujieda M, Ariyoshi N, Yamazaki H, Koizumi W, Tanabe S, Saigenji K, Nagayama S, Ikeda K, Nishioka Y, Kamataki T (2002) A novel mutant allele of the CYP2A6 gene (CYP2A6·11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics. 12(4):299–306 http://www.ncbi.nlm.nih.gov/pubmed/12042667.
42. Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyses D, Dwivedy S, Russo M, Pazdur R (2003) Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 9(1):134–142 http://www.ncbi.nlm.nih.gov/pubmed/12538461.
43. Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16(4):215–237. https://doi.org/10.2165/00003088-198916040-00002.
44. Diasio RB, Lu Z, Zhang R, Shahinian HS (1995) Fluoropyrimidine catabolism. Cancer Treat Rev 20:71–93 http://www.ncbi.nlm.nih.gov/pubmed/8595148.
45. Harris BE, Song R, Soong SJ, Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50(1):197–201. http://www.ncbi.nlm.nih.gov/pubmed/2293556.

46. Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53(17):4004–4009. http://www.ncbi.nlm.nih.gov/pubmed/7689420.

47. Schilsky RL, Hohneker J, Ratain MJ, Janisch L, Smetzer L, Lucas VS, Khor SP, Diasio R, von Hoff DD, Burris HA 3rd (1998) Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol 16(4):1450–1457. https://doi.org/10.1200/JCO.1998.16.4.1450

48. Takechi T, Fujioka A, Matsushima E, Fukushima M (2002) Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 38(9):1271–1277. http://www.ncbi.nlm.nih.gov/pubmed/12044515.

49. Fukushima M, Iizuka K, Jin C, Zhang C, Hong M, Eshima K (2017) Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents. Drug Des Devel Ther 11:1693–1705. https://doi.org/10.2147/DDDT.S128420

50. Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R (2003) Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 9(1):134–142. http://www.ncbi.nlm.nih.gov/pubmed/12538461.

51. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P (2005) Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23(28):6957–6965. https://doi.org/10.1200/JCO.2005.01.917

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.